News

Read about glaucoma treatment advances as positive Phase I results propel a novel eye implant therapy, NT-501, into Phase 2 trials

BrightFocus hosted its 50th Anniversary Celebration and Awards at the Smithsonian’s National Museum of the American Indian in Washington, D.C.

BrightFocus hosted a bipartisan congressional briefing to highlight the importance of funding and diversity in research to improve health equity and cure brain and vision diseases.

A Dutch study of people over age 100 raises new questions about the role of amyloid in Alzheimer’s disease.

Obesity is associated with myriad health risks ranging from heart disease and type 2 diabetes to sleep apnea and stroke. Now, a new study has linked it to age-related macular degeneration

Rexulti (brexpiprazole) is the first FDA-approved treatment for agitation associated with Alzheimer’s in the U.S.